AR015120A1 - Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica - Google Patents

Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica

Info

Publication number
AR015120A1
AR015120A1 ARP980102650A ARP980102650A AR015120A1 AR 015120 A1 AR015120 A1 AR 015120A1 AR P980102650 A ARP980102650 A AR P980102650A AR P980102650 A ARP980102650 A AR P980102650A AR 015120 A1 AR015120 A1 AR 015120A1
Authority
AR
Argentina
Prior art keywords
preparation
amino
methyl
tiazolidin
piridil
Prior art date
Application number
ARP980102650A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of AR015120A1 publication Critical patent/AR015120A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP980102650A 1997-06-05 1998-06-04 Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica AR015120A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
AR015120A1 true AR015120A1 (es) 2001-04-18

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102649A AR008198A1 (es) 1997-06-05 1998-06-04 Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona
ARP980102650A AR015120A1 (es) 1997-06-05 1998-06-04 Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980102649A AR008198A1 (es) 1997-06-05 1998-06-04 Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona

Country Status (29)

Country Link
EP (1) EP0998284A1 (ja)
JP (1) JP2001521553A (ja)
KR (1) KR20010013410A (ja)
CN (3) CN1112926C (ja)
AP (1) AP1214A (ja)
AR (2) AR008198A1 (ja)
AU (1) AU8215098A (ja)
BG (1) BG104048A (ja)
BR (1) BR9810405A (ja)
CA (2) CA2333352A1 (ja)
CO (1) CO4940400A1 (ja)
DZ (1) DZ2510A1 (ja)
EA (1) EA002384B1 (ja)
GB (1) GB9711683D0 (ja)
HU (1) HUP0004070A3 (ja)
ID (1) ID24264A (ja)
IL (1) IL133074A0 (ja)
MX (1) MXPA99011322A (ja)
NO (2) NO995938L (ja)
NZ (2) NZ523725A (ja)
OA (1) OA11306A (ja)
PE (1) PE78899A1 (ja)
PL (1) PL337201A1 (ja)
SK (1) SK164899A3 (ja)
TR (2) TR199902963T2 (ja)
TW (1) TW570797B (ja)
UY (1) UY25032A1 (ja)
WO (1) WO1998055122A1 (ja)
ZA (2) ZA9811572B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
AR008198A1 (es) 1999-12-29
EP0998284A1 (en) 2000-05-10
CA2292629C (en) 2004-01-06
UY25032A1 (es) 1998-11-26
BG104048A (bg) 2000-07-31
PL337201A1 (en) 2000-08-14
AU8215098A (en) 1998-12-21
NO20040738L (no) 2000-02-02
TW570797B (en) 2004-01-11
AP9901696A0 (en) 1999-12-31
EA199901116A1 (ru) 2000-06-26
CN1526391A (zh) 2004-09-08
BR9810405A (pt) 2000-08-29
ZA9811572B (en) 1999-07-22
OA11306A (en) 2003-10-22
HUP0004070A2 (hu) 2002-02-28
CN1430959A (zh) 2003-07-23
TR200002790T2 (tr) 2001-11-21
NZ523725A (en) 2004-09-24
TR199902963T2 (xx) 2000-02-21
NZ513922A (en) 2001-09-28
CN1259050A (zh) 2000-07-05
CA2333352A1 (en) 1998-12-10
DZ2510A1 (fr) 2003-01-25
NO995938L (no) 2000-02-02
NO995938D0 (no) 1999-12-03
CN1112926C (zh) 2003-07-02
WO1998055122A1 (en) 1998-12-10
KR20010013410A (ko) 2001-02-26
ZA984826B (en) 1999-08-03
SK164899A3 (en) 2000-11-07
CA2292629A1 (en) 1998-12-10
MXPA99011322A (es) 2004-12-02
JP2001521553A (ja) 2001-11-06
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
ID24264A (id) 2000-07-13
IL133074A0 (en) 2001-03-19
PE78899A1 (es) 1999-10-22
AP1214A (en) 2003-10-08
EA002384B1 (ru) 2002-04-25
CO4940400A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
RS51343B (sr) Nova kompozicija i njena upotreba
AR015120A1 (es) Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica
EA200702648A1 (ru) Фармацевтическая композиция, пригодная для введения один раз в день
CY1105252T1 (el) Το υδροχλωρικο αλας της 5-[4-[2-(ν-μεθυλο-ν-(2-πυριδυλο)αμινο)-αιθοξυ]βενζυλο]θειαζολιδινο-2,4-διονης
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
CY1107252T1 (el) Τρυγικο αλας παραγωγου της θειζολιδινοδιονης
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AR038417A1 (es) Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral
ECSP034469A (es) Compuesto farmaceutico novedoso
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
GB0021784D0 (en) Novel pharmaceutical
BR0112984A (pt) Sais tartarato de derivado de tiazolidinodiona
HRP20010344B1 (en) Novel method of treatment
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
ECSP034528A (es) Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona
EA200300004A1 (ru) Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
NZ510672A (en) Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione
ECSP003434A (es) Nuevos compuestos
CO5150180A1 (es) Nueva composicion y uso liberacion modificada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal